ZA201003476B - Pyrimidine derivatives for the treatment of asthma,copd,allergic rhinitis,allergic conjunctivitis,atopic dermatitis,cancer,hepatits b,hepatitis c,hiv,hpv,bacterial infections and dermatosis - Google Patents

Pyrimidine derivatives for the treatment of asthma,copd,allergic rhinitis,allergic conjunctivitis,atopic dermatitis,cancer,hepatits b,hepatitis c,hiv,hpv,bacterial infections and dermatosis

Info

Publication number
ZA201003476B
ZA201003476B ZA2010/03476A ZA201003476A ZA201003476B ZA 201003476 B ZA201003476 B ZA 201003476B ZA 2010/03476 A ZA2010/03476 A ZA 2010/03476A ZA 201003476 A ZA201003476 A ZA 201003476A ZA 201003476 B ZA201003476 B ZA 201003476B
Authority
ZA
South Africa
Prior art keywords
hepatits
dermatosis
hpv
copd
hepatitis
Prior art date
Application number
ZA2010/03476A
Other languages
English (en)
Inventor
Nicholas J Bennett
Thomas Mcinally
Tobias Mochel
Stephen Thom
Anna-Karin Tiden
Original Assignee
Astrazeneca Ab
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Dainippon Sumitomo Pharma Co filed Critical Astrazeneca Ab
Publication of ZA201003476B publication Critical patent/ZA201003476B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2010/03476A 2007-11-22 2010-05-17 Pyrimidine derivatives for the treatment of asthma,copd,allergic rhinitis,allergic conjunctivitis,atopic dermatitis,cancer,hepatits b,hepatitis c,hiv,hpv,bacterial infections and dermatosis ZA201003476B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0702577 2007-11-22
US1369907P 2007-12-14 2007-12-14
PCT/SE2008/051334 WO2009067081A1 (en) 2007-11-22 2008-11-21 Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis

Publications (1)

Publication Number Publication Date
ZA201003476B true ZA201003476B (en) 2013-10-30

Family

ID=40667750

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/03476A ZA201003476B (en) 2007-11-22 2010-05-17 Pyrimidine derivatives for the treatment of asthma,copd,allergic rhinitis,allergic conjunctivitis,atopic dermatitis,cancer,hepatits b,hepatitis c,hiv,hpv,bacterial infections and dermatosis

Country Status (35)

Country Link
US (2) US8268990B2 (enExample)
EP (1) EP2222648B1 (enExample)
JP (1) JP5638394B2 (enExample)
KR (1) KR101663326B1 (enExample)
CN (2) CN103342682A (enExample)
AR (1) AR069412A1 (enExample)
AU (1) AU2008326863B2 (enExample)
BR (1) BRPI0819788A2 (enExample)
CA (1) CA2704214C (enExample)
CL (1) CL2008003480A1 (enExample)
CO (1) CO6270324A2 (enExample)
CR (1) CR11451A (enExample)
CY (1) CY1113846T1 (enExample)
DK (1) DK2222648T3 (enExample)
DO (1) DOP2010000153A (enExample)
EA (1) EA018121B1 (enExample)
EC (1) ECSP10010294A (enExample)
ES (1) ES2401401T3 (enExample)
HN (1) HN2010001059A (enExample)
HR (1) HRP20130174T1 (enExample)
IL (1) IL205513A0 (enExample)
ME (1) ME01515B (enExample)
MX (1) MX2010005435A (enExample)
NZ (1) NZ585313A (enExample)
PE (1) PE20091236A1 (enExample)
PL (1) PL2222648T3 (enExample)
PT (1) PT2222648E (enExample)
RS (1) RS52694B (enExample)
SA (1) SA08290741B1 (enExample)
SI (1) SI2222648T1 (enExample)
TW (1) TWI461198B (enExample)
UA (1) UA99484C2 (enExample)
UY (1) UY31481A1 (enExample)
WO (1) WO2009067081A1 (enExample)
ZA (1) ZA201003476B (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06011080A (es) 2004-03-26 2007-04-16 Astrazeneca Ab Compuesto de 8-oxoadenina 9-sustituido.
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
EP2041135A4 (en) * 2006-07-05 2010-12-01 Astrazeneca Ab As TLR7 MODULATORS, 8-OXOADENINE DERIVATIVES WORK
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
WO2008114006A1 (en) * 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
JP5480637B2 (ja) * 2007-03-19 2014-04-23 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
TW200902018A (en) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
US8044056B2 (en) * 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
EP2155743B1 (en) * 2007-05-08 2012-08-29 AstraZeneca AB Imidazoquinolines with immuno-modulating properties
NZ582090A (en) * 2007-06-29 2012-05-25 Gilead Sciences Inc Purine derivatives and their use as modulators of toll-like receptor 7
BRPI0815979A2 (pt) 2007-08-28 2017-06-13 Irm Llc compostos e composições com inibidores de quinase, bem como uso dos mesmos
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
UY31531A1 (es) 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
EA026557B1 (ru) 2008-12-09 2017-04-28 Джилид Сайэнс, Инк. Промежуточные соединения для получения модуляторов толл-подобных рецепторов
BRPI1010937A2 (pt) 2009-05-21 2019-09-24 Astrazeneca Ab composto, uso de um composto, e, método para tratar câncer
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
CN102753177A (zh) * 2009-08-17 2012-10-24 纪念斯隆-凯特琳癌症中心 热休克蛋白结合化合物、组合物以及其制备和使用方法
NZ598654A (en) 2009-09-02 2014-05-30 Novartis Ag Immunogenic compositions including tlr activity modulators
PE20121091A1 (es) 2009-10-22 2012-08-17 Gilead Sciences Inc Derivados de purina o deazapurina utiles en el tratamiento de (inter alia) infecciones virales
EP2507237A1 (en) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2011079016A1 (en) * 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
JP2013147428A (ja) * 2010-04-27 2013-08-01 Dainippon Sumitomo Pharma Co Ltd 新規２−ヘテロアリール単環ピリミジン誘導体
AU2011295853A1 (en) 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
JP2013542916A (ja) * 2010-11-19 2013-11-28 大日本住友製薬株式会社 環状アミド化合物および疾患の処置におけるその使用
WO2012066335A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012067269A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012066336A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
ES2627433T3 (es) 2010-12-17 2017-07-28 Sumitomo Dainippon Pharma Co., Ltd. Derivados de purina
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
ES2624288T3 (es) 2011-01-21 2017-07-13 Eisai R&D Management Co., Ltd. Métodos y compuestos útiles en la síntesis de derivados de aminodihidrotiazina condensados
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
SMT202100483T1 (it) 2011-04-08 2021-09-14 Janssen Sciences Ireland Unlimited Co Derivati di pirimidina per il trattamento di infezioni virali
US8916575B2 (en) * 2011-05-18 2014-12-23 Janssen R&D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
KR20140066212A (ko) 2011-09-01 2014-05-30 노파르티스 아게 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물
LT2776439T (lt) 2011-11-09 2018-10-10 Janssen Sciences Ireland Uc Purino dariniai, skirti virusinų infekcijų gydymui
ES2716811T3 (es) 2012-02-08 2019-06-17 Janssen Sciences Ireland Unlimited Co Derivados piperidinopirimidínicos para el tratamiento de infecciones víricas
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP2822589A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of rabies virus immunogens
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
MX358172B (es) * 2012-05-03 2018-08-08 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
DK2850067T3 (da) * 2012-05-18 2017-11-06 Sumitomo Dainippon Pharma Co Ltd Carboxylsyreforbindelser
KR102207888B1 (ko) 2012-07-13 2021-01-26 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염증의 치료를 위한 거대환식 푸린
NZ703731A (en) * 2012-08-10 2018-03-23 Janssen Sciences Ireland Uc Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
EP2712866A1 (en) * 2012-10-01 2014-04-02 Centre National de la Recherche Scientifique (CNRS) 1,2,4-triazine derivatives for the treatment of viral infections
WO2014053595A1 (en) 2012-10-05 2014-04-10 Janssen R&D Ireland Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PT2906563T (pt) * 2012-10-10 2018-05-23 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina para o tratamento de infeções virais e outras doenças
WO2014057132A1 (en) 2012-10-12 2014-04-17 Novartis Ag Non-cross-linked acellular pertussis antigens for use in combination vaccines
NZ748345A (en) 2012-11-16 2020-04-24 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
ES2670863T3 (es) 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll
KR102225233B1 (ko) 2013-02-21 2021-03-09 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
UA115588C2 (uk) 2013-03-29 2017-11-27 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Макроциклічні деазаоксипурини для лікування вірусних інфекцій
CA2911296A1 (en) 2013-05-10 2014-11-13 Wayne Volkmuth Avoiding narcolepsy risk in influenza vaccines
WO2014187932A1 (en) * 2013-05-24 2014-11-27 Janssen R&D Ireland Pyridone derivatives for the treatment of viral infections and further diseases
NO3030563T3 (enExample) 2013-06-27 2018-01-06
MX368625B (es) 2013-07-30 2019-10-08 Janssen Sciences Ireland Uc Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales.
US10328140B2 (en) 2014-03-26 2019-06-25 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
AU2015259173B2 (en) 2014-05-13 2019-09-05 Memorial Sloan Kettering Cancer Center Hsp70 modulators and methods for making and using the same
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
PT3194401T (pt) 2014-09-16 2020-12-23 Gilead Sciences Inc Formas sólidas de modulador de recetor tipo toll
CN105111151B (zh) * 2015-04-17 2018-09-28 成都理工大学 作为PPAR-γ调节剂的氨基嘧啶衍生物
WO2016193405A1 (en) 2015-06-03 2016-12-08 Affiris Ag Il-23-p19 vaccines
CA2991544A1 (en) 2015-07-07 2017-01-12 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
HUE055079T2 (hu) 2015-10-07 2021-10-28 Sumitomo Dainippon Pharma Co Ltd Pirimidin vegyületek
MA45539A (fr) 2016-07-01 2019-05-08 Janssen Sciences Ireland Unlimited Co Dihydropyranopyrimidines pour le traitement d'infections virales
WO2018060317A1 (en) 2016-09-29 2018-04-05 Janssen Sciences Ireland Uc Pyrimidine prodrugs for the treatment of viral infections and further diseases
WO2018106606A1 (en) * 2016-12-05 2018-06-14 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
US10786502B2 (en) * 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
US11253476B2 (en) 2017-03-29 2022-02-22 Sumitomo Dainippon Pharma Co., Ltd. Vaccine adjuvant formulation
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
EP3802519A1 (en) * 2018-06-04 2021-04-14 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7
CN112512590A (zh) * 2018-06-04 2021-03-16 阿普罗斯治疗公司 Tlr7肽缀合物
TW202011986A (zh) 2018-07-23 2020-04-01 公益財團法人日本健康科學振興財團 包含流感疫苗之組合物
MX2021012201A (es) 2019-04-05 2022-01-06 Sumitomo Pharma Co Ltd Adyuvante soluble en agua.
WO2020255039A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
US20240000707A1 (en) * 2020-11-18 2024-01-04 Lonza Bend Inc. Inhalable dry powder formulations comprising angiogenesis inhibitors
CN117379535B (zh) * 2023-12-08 2024-03-15 中国人民解放军总医院第二医学中心 肝细胞生长因子在制备变应性鼻炎的药物中的应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2657206A (en) * 1951-07-30 1953-10-27 Burroughs Wellcome Co 2, 4-diamino-5-aryloxy-pyrimidines
GB1375162A (enExample) 1970-10-22 1974-11-27
GB1546937A (en) * 1976-07-29 1979-05-31 Beecham Group Ltd 2,4-diaminopyrimidine derivatives
US4505910A (en) * 1983-06-30 1985-03-19 American Home Products Corporation Amino-pyrimidine derivatives, compositions and use
GR82004B (enExample) * 1983-06-30 1984-12-12 American Home Prod
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) * 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL78643A0 (en) * 1985-05-02 1986-08-31 Wellcome Found Purine derivatives,their preparation and pharmaceutical compositions containing them
DE3603577A1 (de) * 1986-02-06 1987-08-13 Joachim K Prof Dr Seydel Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit
GB8900382D0 (en) * 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
US5290933A (en) * 1989-04-26 1994-03-01 Smithkline & French Laboratories Limited Phenylpyrimidone derivatives
JPH08165292A (ja) 1993-10-07 1996-06-25 Techno Res Kk アデニン誘導体、その製造法及び用途
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
JPH10507171A (ja) * 1994-10-05 1998-07-14 カイロサイエンス・リミテッド Ｐｎｐインヒビターとしてのプリンおよびグアニン化合物
ES2232871T3 (es) * 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Nuevos derivados de purina.
AU732361B2 (en) * 1997-11-28 2001-04-26 Dainippon Sumitomo Pharma Co., Ltd. Novel heterocyclic compounds
TW572758B (en) * 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
JP2003504301A (ja) 1998-04-01 2003-02-04 ブリストル−マイヤーズ スクイブ ファーマ カンパニー インテグリンアンタゴニスト
ES2221414T3 (es) * 1998-08-27 2004-12-16 Sumitomo Pharmaceuticals Company, Limited Derivados de pirimidina.
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
AU6111000A (en) 1999-07-22 2001-02-13 Vertex Pharmaceuticals Incorporated Inhibitors of viral helcase
AU2001271867A1 (en) * 2000-07-07 2002-01-21 Neotherapeutics, Inc. Methods for treatment of conditions affected by activity of multidrug transporters
DE60228229D1 (de) * 2001-04-17 2008-09-25 Dainippon Sumitomo Pharma Co Neue adeninderivate
US7115373B2 (en) * 2002-06-27 2006-10-03 Genox Research, Inc. Method of testing for atopic dermatitis by measuring expression of the NOR-1 gene
CA2497765A1 (en) 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Co., Ltd. 8-hydroxy substituted adenine compounds and uses thereof
EP1606304A4 (en) * 2003-03-12 2006-09-27 Evogene Ltd Gene expression regulating regulatory nucleotide sequences and constructs and methods thereof
EP1635846A4 (en) * 2003-06-20 2009-01-28 Coley Pharm Gmbh SMALL MOLECULAR TLR (TOLL-LIKE RECEPTOR) ANTAGONISTS
ZA200510028B (en) * 2003-06-20 2007-03-28 Coley Pharm Gmbh Small molicule toll-like receptor (TLR) antagonists
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
BRPI0414045A (pt) * 2003-09-05 2006-10-24 Anadys Pharmaceuticals Inc administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c
WO2005092892A1 (ja) 2004-03-26 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. ８−オキソアデニン化合物
MXPA06011080A (es) 2004-03-26 2007-04-16 Astrazeneca Ab Compuesto de 8-oxoadenina 9-sustituido.
KR100700676B1 (ko) 2005-06-24 2007-03-28 (주) 비엔씨바이오팜 6―（4―치환된―아닐리노）피리미딘 유도체, 그 제조방법및 이를 포함하는 항바이러스용 약학적 조성물
US7759350B2 (en) 2005-09-15 2010-07-20 Orchid Research Laboratories Ltd. Pyrimidine carboxamides
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
EP1939201A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
WO2007034817A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
TW200745114A (en) * 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
WO2007034882A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
JPWO2007034881A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
WO2007034916A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
WO2008001070A1 (en) 2006-06-30 2008-01-03 Astrazeneca Ab Pyrimidine derivatives useful in the treatment of cancer
EP2041135A4 (en) 2006-07-05 2010-12-01 Astrazeneca Ab As TLR7 MODULATORS, 8-OXOADENINE DERIVATIVES WORK
CL2007002231A1 (es) 2006-08-02 2008-04-11 Basf Ag Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico.
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
WO2008083465A1 (en) 2007-01-08 2008-07-17 University Health Network Pyrimidine derivatives as anticancer agents
WO2008114006A1 (en) 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
JP5480637B2 (ja) * 2007-03-19 2014-04-23 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
US8044056B2 (en) * 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
TW200902018A (en) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
EP2155743B1 (en) 2007-05-08 2012-08-29 AstraZeneca AB Imidazoquinolines with immuno-modulating properties
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
UY31531A1 (es) 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
CA2711769A1 (en) 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co. Ltd. Method for preparing adenine compound
US20110054168A1 (en) 2008-01-17 2011-03-03 Ayumu Kurimoto Method for preparing adenine compound
WO2010033074A1 (en) 2008-09-18 2010-03-25 Astrazeneca Ab Use of a tlr7 agonist for the treatment of cancer
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
EP2507237A1 (en) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)

Also Published As

Publication number Publication date
ME01515B (me) 2014-04-20
EP2222648A4 (en) 2010-12-08
SI2222648T1 (sl) 2013-06-28
PL2222648T3 (pl) 2013-05-31
RS52694B (sr) 2013-08-30
MX2010005435A (es) 2010-06-11
HN2010001059A (es) 2012-08-24
AR069412A1 (es) 2010-01-20
TW200927123A (en) 2009-07-01
UA99484C2 (ru) 2012-08-27
JP2011504497A (ja) 2011-02-10
SA08290741B1 (ar) 2012-01-24
US20090209524A1 (en) 2009-08-20
KR20100095610A (ko) 2010-08-31
NZ585313A (en) 2012-04-27
EP2222648A1 (en) 2010-09-01
HK1147749A1 (en) 2011-08-19
CN101925584B (zh) 2013-04-17
CA2704214C (en) 2016-05-24
DK2222648T3 (da) 2013-03-18
AU2008326863A1 (en) 2009-05-28
CR11451A (es) 2010-10-05
AU2008326863B2 (en) 2012-01-19
PT2222648E (pt) 2013-03-07
ES2401401T3 (es) 2013-04-19
US8268990B2 (en) 2012-09-18
JP5638394B2 (ja) 2014-12-10
WO2009067081A1 (en) 2009-05-28
CA2704214A1 (en) 2009-05-28
CL2008003480A1 (es) 2009-06-05
EA018121B1 (ru) 2013-05-30
HRP20130174T1 (hr) 2013-03-31
TWI461198B (zh) 2014-11-21
BRPI0819788A2 (pt) 2015-05-05
CY1113846T1 (el) 2016-07-27
US20130045955A1 (en) 2013-02-21
CO6270324A2 (es) 2011-04-20
PE20091236A1 (es) 2009-09-16
CN103342682A (zh) 2013-10-09
US8765939B2 (en) 2014-07-01
KR101663326B1 (ko) 2016-10-06
IL205513A0 (en) 2010-12-30
DOP2010000153A (es) 2010-07-15
EA201000830A1 (ru) 2011-02-28
EP2222648B1 (en) 2013-01-09
UY31481A1 (es) 2009-07-17
CN101925584A (zh) 2010-12-22
ECSP10010294A (es) 2010-07-30

Similar Documents

Publication Publication Date Title
ZA201003476B (en) Pyrimidine derivatives for the treatment of asthma,copd,allergic rhinitis,allergic conjunctivitis,atopic dermatitis,cancer,hepatits b,hepatitis c,hiv,hpv,bacterial infections and dermatosis
SI2193131T1 (sl) Imidazo(1,2-A)pirazin spojine za zdravljenje virusnih okuĹľb kot je hepatitis
SG11201502622VA (en) PYRROLO[3,2-<i>D</i>]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
NZ596118A (en) Disaccharin, difumaric acid, di-1-hydroxy-2-naphthoic acid and mono-benzoic acid salts of 4- (dimethylamino)butyl 2- (4- ( (2-amino-4-methyl-6- (pentylamino) pyrimidin- 5 -yl) methyl) phenyl)acetate
WO2011068941A3 (en) Proline derivatives
PL2694484T3 (pl) Pochodne pirymidyny do leczenia zakażeń wirusowych
ZA201005737B (en) Methods of treating viral infections
IL200848A0 (en) Solid dispersions of imatinib and processes for producing the same
PL2547964T3 (pl) Leczenie astmy, alergicznego nieżytu nosa i poprawa jakości snu poprzez stosowanie laminarnego przepływu powietrza kontrolowanego temperaturą
EP2447229A4 (en) GLASS SHIELD AGAINST THERMAL RAYS, AND LAMINATED SHIELDING GLASS AGAINST THERMAL RAYS
EP2194166A4 (en) QUARTZ GLASS LEVER, PROCESS FOR ITS MANUFACTURE AND PRODUCTION PROCESS
IL195272A0 (en) Methods and compositions for the treatment of viral infections
PL2444481T3 (pl) Mikroorganizm wytwarzający O-fosfoserynę oraz sposób otrzymywania L-cysteiny lub jej pochodnych z O-fosfoseryny z zastosowaniem tego mikroorganizmu”
ZA200904068B (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
EP2164515A4 (en) PROCESS FOR TREATING ATOPIC ECZEMA
IL218415A0 (en) Fluoro-substituted 3,5-dicyano-4-(1h-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof
WO2011100282A3 (en) Imatinib mesylate polymorphs
GB2464741B (en) FETs, semiconductor devices and their methods of manufacture
SI2766367T1 (sl) 4-amino-3-fenilamino-6-fenilpirazol(3,4-D)primidinski derivati za zdravljenje virusnih okužb, zlasti pikornavirusnih okužb
GB0608792D0 (en) Method for treatment and prophylaxis of viral influenza infections
HK1165996A (en) Compounds and methods for treating cancer and viral infections
HK1157264A (en) Devices for treatment of viral infections
CU23976B1 (es) Derivados de pirimidina para el tratamiento de asma, epoc, rinitis alérgica, conjuntivitis alérgica, dermatitis atópica, cáncer, hepatitis b, hepatitis c, vih, vph, infecciones bacterianas y dermatosis
EP2415768B8 (en) Tricyclic condensed heterocyclic compound, method for producing same, and use thereof
HK1139145A (en) Novel macrocyclic inhibitors of hepatitis c virus replication